Estimation of Health State Utility Values for Immunoglobulin A Nephropathy: A Time Trade-Off Analysis

Zheng-Yi Zhou (), Mark E. Bensink, Nisha C. Hazra, Chunyi Xu, Bruce Hendry, Claire C. Sharpe and Mo Zhou
Additional contact information
Zheng-Yi Zhou: Analysis Group
Mark E. Bensink: Travere Therapeutics, Inc.
Nisha C. Hazra: Analysis Group
Chunyi Xu: Analysis Group
Bruce Hendry: Travere Therapeutics, Inc.
Claire C. Sharpe: King’s College Hospital
Mo Zhou: Analysis Group

PharmacoEconomics - Open, 2025, vol. 9, issue 1, No 8, 83-92

Abstract: Abstract Background Immunoglobulin A nephropathy (IgAN) is a rare progressive disease that can lead to kidney failure. The current study aimed to estimate health state utility values for IgAN from a UK societal perspective. Methods We used the time trade-off (TTO) method to derive utility values for various health states in IgAN, defined based on chronic kidney disease (CKD) stage, proteinuria, dialysis, and nephrotic syndrome (CKD stages 1–4, proteinuria

Date: 2025
References: View references in EconPapers View complete reference list from CitEc
Citations:

Downloads: (external link)
http://link.springer.com/10.1007/s41669-024-00527-1 Abstract (text/html)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:spr:pharmo:v:9:y:2025:i:1:d:10.1007_s41669-024-00527-1

Ordering information: This journal article can be ordered from
http://www.springer.com/adis/journal/41669

DOI: 10.1007/s41669-024-00527-1

Access Statistics for this article

PharmacoEconomics - Open is currently edited by Timothy Wrightson and Christopher Carswell

More articles in PharmacoEconomics - Open from Springer
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().